Global Markets
Catalent: GLP-1 and gene therapy to counter dwindling COVID returns
Global MarketsCatalent: GLP-1 and gene therapy to counter dwindling COVID returnsCatalent: GLP-1 and gene therapy to counter dwindling COVID returns
Catalent suffered another drop in biologics revenues post-COVID, but is confident its increased support of GLP-1 programs will drive sales.